lymphokine activated killer cells

Summary

Summary: Cytolytic lymphocytes with the unique capacity of killing natural killer (NK)-resistant fresh tumor cells. They are interleukin-2-activated NK cells that have no MHC (major histocompatibility complex) restriction or need for antigen stimulation. LAK cells are used for adoptive immunotherapy in cancer patients.

Top Publications

  1. ncbi The human liver contains multiple populations of NK cells, T cells, and CD3+CD56+ natural T cells with distinct cytotoxic activities and Th1, Th2, and Th0 cytokine secretion patterns
    D G Doherty
    Education and Research Centre and Liver Unit, St Vincent s Hospital, Dublin, Ireland
    J Immunol 163:2314-21. 1999
  2. ncbi A "chimeric" C57l-derived Ly49 inhibitory receptor resembling the Ly49D activation receptor
    I K Mehta
    Immunology Program and Rheumatology Division, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Cell Immunol 209:29-41. 2001
  3. ncbi Doxorubicin plus interleukin-2 chemoimmunotherapy against breast cancer in mice
    Andrew Ewens
    Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Cancer Res 66:5419-26. 2006
  4. ncbi Evidence for the involvement of CD44 in endothelial cell injury and induction of vascular leak syndrome by IL-2
    A Q Rafi-Janajreh
    Department of Biology, Virginia Maryland Regional College of Veterinary Medicine, Virginia Tech, Blacksburg 24061, USA
    J Immunol 163:1619-27. 1999
  5. ncbi Natural killer (NK) and lymphokine-activated killer (LAK) cell functions from healthy dogs and 29 dogs with a variety of spontaneous neoplasms
    Jürgen Funk
    Institut für Veterinär Pathologie, Justus Liebig Universitat, 35392 Giessen, Germany
    Cancer Immunol Immunother 54:87-92. 2005
  6. pmc Interleukin-12 up-regulates perforin- and Fas-mediated lymphokine-activated killer activity by intestinal intraepithelial lymphocytes
    E C Ebert
    UMDNJ Robert Wood Johnson Medical School, New Brunswick, NJ, USA
    Clin Exp Immunol 138:259-65. 2004
  7. ncbi Inhibition of immunosuppressive effects of melanoma-inhibiting activity (MIA) by antisense techniques
    Piotr Jachimczak
    Antisense Pharma GmbH, Regensburg, Germany
    Int J Cancer 113:88-92. 2005
  8. ncbi Natural killer cells and their receptors
    Derek Middleton
    Northern Ireland Regional Histocompatibility and Immunogenetics Laboratory, Belfast City Hospital, Belfast, UK
    Transpl Immunol 10:147-64. 2002
  9. ncbi A GFP-transfected HFWT cell line, GHINK-1, as a novel target for non-RI activated natural killer cytotoxicity assay
    Hideki Harada
    RIKEN Cell Bank, RIKEN The Institute of Physical and Chemical Research, Koyadai 3 1 1, Tsukuba Science City, 305 0074, Japan
    Hum Cell 17:43-8. 2004
  10. ncbi The effects of anti-histone H1 antibody on immune cells responsible for rejection reaction
    Li Wen Hsu
    Department of Surgery, Liver Transplant Center, Kaohsiung Chang Gung Memorial Hospital, 123 Ta Pei Rd, Niao Sung Hsiang, Kaohsiung Hsien 833, Taiwan
    Mol Immunol 42:1155-64. 2005

Research Grants

  1. Regulation of urokinase receptor expression in colon cancer
    Douglas D Boyd; Fiscal Year: 2010
  2. DEVELOPING T CELLS CLONES CYTOTOXIC TO SARCOMAS
    Michael Mastrangelo; Fiscal Year: 1990
  3. IL7 AND IL7R TARGETED THERAPEUTIC AGENTS FOR LEUKEMIA
    John Murphy; Fiscal Year: 2000
  4. Lymphodepletion for Melanoma Patients
    Marc Ernstoff; Fiscal Year: 2007
  5. M40403 and IL-2 Induced Hypotension
    Daniela Salvemini; Fiscal Year: 2001
  6. HUMAN LYMPHOKINE-ACTIVATED KILLER CELLS
    JANET RANSOM; Fiscal Year: 1991
  7. THE CELLULAR STRESS RESPONSE IN VIRAL ENCEPHALITIS
    Michael Oglesbee; Fiscal Year: 2008
  8. T CELL ACTIVATION FOR CANCER IMMUNOTHERAPY
    Alfred Chang; Fiscal Year: 2008
  9. Role of DPPI & Serine Proteases in Inflammatory Diseases
    Christine Pham; Fiscal Year: 2007
  10. T CELL THERAPY OF HUMAN RENAL CELL CANCER
    Alfred Chang; Fiscal Year: 2007

Detail Information

Publications211 found, 100 shown here

  1. ncbi The human liver contains multiple populations of NK cells, T cells, and CD3+CD56+ natural T cells with distinct cytotoxic activities and Th1, Th2, and Th0 cytokine secretion patterns
    D G Doherty
    Education and Research Centre and Liver Unit, St Vincent s Hospital, Dublin, Ireland
    J Immunol 163:2314-21. 1999
    ....
  2. ncbi A "chimeric" C57l-derived Ly49 inhibitory receptor resembling the Ly49D activation receptor
    I K Mehta
    Immunology Program and Rheumatology Division, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Cell Immunol 209:29-41. 2001
    ..Therefore, this apparently "chimeric" Ly49 molecule serologically resembles an NK cell activation receptor but functions as an inhibitory receptor...
  3. ncbi Doxorubicin plus interleukin-2 chemoimmunotherapy against breast cancer in mice
    Andrew Ewens
    Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Cancer Res 66:5419-26. 2006
    ..The efficacy of this nontoxic treatment and the potential to be able to predict which individual is responding to treatment are characteristics that make this chemoimmunotherapy attractive for clinical testing...
  4. ncbi Evidence for the involvement of CD44 in endothelial cell injury and induction of vascular leak syndrome by IL-2
    A Q Rafi-Janajreh
    Department of Biology, Virginia Maryland Regional College of Veterinary Medicine, Virginia Tech, Blacksburg 24061, USA
    J Immunol 163:1619-27. 1999
    ..Blocking CD44 in vivo may offer a novel therapeutic approach to prevent endothelial cell injury by cytotoxic lymphocytes in a variety of clinical disease models...
  5. ncbi Natural killer (NK) and lymphokine-activated killer (LAK) cell functions from healthy dogs and 29 dogs with a variety of spontaneous neoplasms
    Jürgen Funk
    Institut für Veterinär Pathologie, Justus Liebig Universitat, 35392 Giessen, Germany
    Cancer Immunol Immunother 54:87-92. 2005
    ..Our findings suggest that the dog could also serve as a relevant large animal model for cancer immunotherapy with IL-2...
  6. pmc Interleukin-12 up-regulates perforin- and Fas-mediated lymphokine-activated killer activity by intestinal intraepithelial lymphocytes
    E C Ebert
    UMDNJ Robert Wood Johnson Medical School, New Brunswick, NJ, USA
    Clin Exp Immunol 138:259-65. 2004
    ..This study shows that LAK activity, carried out by the CD94(+) IELs, involves perforin, FL and TNF-alpha. IL-12 up-regulates the first two mechanisms of action, showing for the first time its effect on FL production and lytic activity...
  7. ncbi Inhibition of immunosuppressive effects of melanoma-inhibiting activity (MIA) by antisense techniques
    Piotr Jachimczak
    Antisense Pharma GmbH, Regensburg, Germany
    Int J Cancer 113:88-92. 2005
    ..Antagonization of MIA activity using antisense techniques may represent a novel therapeutic strategy for treatment of malignant melanomas...
  8. ncbi Natural killer cells and their receptors
    Derek Middleton
    Northern Ireland Regional Histocompatibility and Immunogenetics Laboratory, Belfast City Hospital, Belfast, UK
    Transpl Immunol 10:147-64. 2002
    ..The roles that NK cells and their receptors have with various facets of transplantation, disease, pregnancy and control of virus infection in humans are described...
  9. ncbi A GFP-transfected HFWT cell line, GHINK-1, as a novel target for non-RI activated natural killer cytotoxicity assay
    Hideki Harada
    RIKEN Cell Bank, RIKEN The Institute of Physical and Chemical Research, Koyadai 3 1 1, Tsukuba Science City, 305 0074, Japan
    Hum Cell 17:43-8. 2004
    ..Because it does not require separation of the remaining live target cells by centrifugation, the non-radioisotopic GFP release assay with GHINK-1 cells is a convenient alternative for monitoring human activated NK killing activity...
  10. ncbi The effects of anti-histone H1 antibody on immune cells responsible for rejection reaction
    Li Wen Hsu
    Department of Surgery, Liver Transplant Center, Kaohsiung Chang Gung Memorial Hospital, 123 Ta Pei Rd, Niao Sung Hsiang, Kaohsiung Hsien 833, Taiwan
    Mol Immunol 42:1155-64. 2005
    ..These results suggest that the use of anti-histone H1 Abs might be a useful strategy for the development of a form of immunosuppression...
  11. ncbi Human natural killer cells: a comprehensive review
    Joseph G Sinkovics
    Cancer Institute, St Joseph s Hospital, Tampa, FL 33607 6387, USA
    Int J Oncol 27:5-47. 2005
    ..The exemplary case history of another patient with NK cell lymphoma-leukemia treated by the authors is presented...
  12. ncbi Dynamics of proinflammatory cytokines serum levels during viral hepatitis type A
    Hanna Fota-Markowska
    Chair and Department of Infectious Diseases, Skubiszewski Medical University of Lublin
    Ann Univ Mariae Curie Sklodowska Med 59:209-13. 2004
    ..The assessment of IL-2, sIL-2R and IL-4 serum levels can be helpful in examining the cellular response in viral hepatitis A infection...
  13. pmc A subpopulation of B220+ cells in murine bone marrow does not express CD19 and contains natural killer cell progenitors
    A Rolink
    Basel Institute for Immunology, Switzerland
    J Exp Med 183:187-94. 1996
    ..The implications of these findings for studies on B lymphopoiesis are discussed. It is suggested that the CD19-specific monoclonal antibody is more reliable, as in humans, than B220(CD45R) to detect B lineage cells in mice...
  14. ncbi Killing of laminin receptor-positive human lung cancers by tumor infiltrating lymphocytes bearing gammadelta(+) t-cell receptors
    M Ferrarini
    Laboratori Immunoterapia Adottiva, Istituto Scientifico H S Raffaele
    J Natl Cancer Inst 88:436-41. 1996
    ..The infiltration of gammadelta(+) TILs at lung tumor sites may represent a first line of defense against cells undergoing malignant transformation...
  15. ncbi Interleukin-15 induces the expression of mRNAs of cytolytic mediators and augments cytotoxic activities in primary murine lymphocytes
    W Ye
    Laboratory of Cellular Physiology and Immunology, Rockefeller University, New York, New York 10021, USA
    Cell Immunol 174:54-62. 1996
    ..The inadequate cytolytic activity of IL-15-stimulated lymphocytes may in part be due to the less efficient production of cytolytic mediator proteins, e.g., perforin and granzyme A, in these cells...
  16. ncbi IL-2-activated cord blood mononuclear cells
    S Derzic
    Children s Hospital of Orange County Research Institute, Orange, California 91006, USA
    Cytotherapy 7:408-16. 2005
    ..This feasible approach to immunotherapy merits further pre-clinical investigations using human tumor models of hematologic malignancy...
  17. ncbi Gs protein-coupled adenosine receptor signaling and lytic function of activated NK cells
    Tatiana Raskovalova
    Department of Pathology and University of Pittsburgh Cancer Institute, University of Pittsburgh, PA 15213, USA
    J Immunol 175:4383-91. 2005
    ..The elevated intratumor levels of adenosine might inhibit the antitumor effects of activated NK cells...
  18. ncbi Involvement of MHC class I molecule and ICAM-1 in the enhancement of adhesion and cytotoxic susceptibility to immune effector cells of tumor cells transfected with the interleukin (IL)-2, IL-4 or IL-6 gene
    X Cao
    Department of Immunology, Second Military Medical University, Shanghai, PR China
    J Cancer Res Clin Oncol 123:602-8. 1997
    ....
  19. ncbi Mycophenolate mofetil does not suppress the graft-versus-leukemia effect or the activity of lymphokine-activated killer (LAK) cells in a murine model
    Michael Y Shapira
    Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Hebrew University Medical Center, PO Box 12000, 91120, Jerusalem, Israel
    Cancer Immunol Immunother 54:383-8. 2005
    ..Mycophenolate mofetil (MMF) is becoming a standard of care in SCT recipients for better prevention of GVHD as well as for promoting stem cell engraftment...
  20. ncbi Evidence for the involvement of Fas ligand and perforin in the induction of vascular leak syndrome
    A Q Rafi
    Department of Biology, Virginia Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg 24061, USA
    J Immunol 161:3077-86. 1998
    ..The current study demonstrates for the first time that perforin and Fas ligand may actively participate in endothelial cell injury and induction of VLS in a variety of organs...
  21. ncbi Adoptive immunotherapy of cancer using activated autologous lymphocytes--current status and new strategies
    Yoshiyuki Yamaguchi
    Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University
    Hum Cell 16:183-9. 2003
    ..Thus, more understanding of antigen-presentation and -recognition mechanisms and immune regulation systems may promote clinical applications of AIT to establish a novel modality of cancer treatment...
  22. ncbi Activated natural killer cells adhere to cultured hippocampal neurons and affect the dendritic morphology
    Sanae Hasegawa
    Department of Physiology, Graduate School of Medicine, University of Tokyo, 7 3 1 Hongo, Bunkyo, Tokyo 113 0033, Japan
    J Neuroimmunol 151:126-36. 2004
    ..These results suggest that infiltrating immune cells can form direct adhesive connections with CNS neurons and affect their dendritic morphology...
  23. ncbi Cumulative inhibition of NK cells and T cells resulting from engagement of multiple inhibitory Ly49 receptors
    T Hanke
    Institute for Virology and Immunobiology, University of Wurzburg, Wurzburg, Germany
    J Immunol 166:3002-7. 2001
    ..They have intriguing implications concerning NK cell tolerance and reactivity toward cells with extinguished expression of a limited number of class I molecules...
  24. ncbi Immunomodulation in a treatment program including pre- and post-operative interleukin-2 and chemotherapy for childhood osteosarcoma
    Roberto Luksch
    Department of Medical Oncology, Pediatric Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Tumori 89:263-8. 2003
    ..An additional aim was to assess whether any correlation between the immune modifications and the clinical outcome could be found...
  25. ncbi Locoregional immunochemotherapy in hepatocellular carcinoma
    J Kountouras
    Department of Medicine, Second Medical Clinic, Aristotle University of Thessaloniki, Ippokration Hospital, Thessaloniki, Greece
    Hepatogastroenterology 49:1109-12. 2002
    ..Recent data point to the potential of considering intratumoral or intravascular use of adenovirus carrying interleukin-12 gene, and/or p53-based gene therapy as possible therapeutic strategies in patients with hepatocellular carcinoma...
  26. ncbi Differential involvement of CD40, CD80, and major histocompatibility complex class I molecules in cytotoxicity induction and interferon-gamma production by human natural killer effectors
    Giuseppe Terrazzano
    Cattedra di Immunologia, Dipartimento di Biologia e Patologia Cellulare e Molecolare, Universita di Napoli Federico II, Italy
    J Leukoc Biol 72:305-11. 2002
    ..These data provide a possible mechanism underlying functional interactions between NK lymphocytes and CD40/CD80-expressing cell targets, as represented by dendritic cells...
  27. ncbi Activated, but not resting, T cells can be recognized and killed by syngeneic NK cells
    Brian A Rabinovich
    Department of Medical Biophysics, Ontario Cancer Institute, Toronto, Canada
    J Immunol 170:3572-6. 2003
    ..Our data provide a basis for studying a role for NK cells in T cell regulation...
  28. ncbi Inhibition of natural killer cytotoxicity in vitro by clinical grade serine protease inhibitors
    Mitsuteru Yamamoto
    Blood Transfusion Division, Kobe University Hospital, Japan
    Haematologia (Budap) 32:103-11. 2002
    ..None of these agents inhibited lymphokine-activated killer cell activity. In clinical applications, it should be noted that some protease inhibitors have been proven to have immunosuppressive effects...
  29. ncbi [Immunoprotective effect of IL-2 and B7-1 gene co-transfected liver cancer vaccines on hepatocarcinogenesis in mice]
    Ningling Ge
    Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai 200032, China
    Zhonghua Gan Zang Bing Za Zhi 10:417-20. 2002
    ..To study the immunoprotective effect of IL-2 and B7-1 gene co-transfected liver cancer vaccine on hepatocarcinogenesis in mice...
  30. ncbi Immunosensitization of resistant human tumor cells to cytotoxicity by tumor infiltrating lymphocytes
    Patrick Frost
    Department of Psychiatry, Neuropsychiatric Institute, Jonsson Comprehensive Cancer Center, UCLA School of Medicine, Los Angeles, CA 90095 1761, USA
    Int J Oncol 22:431-7. 2003
    ..Further, in vivo sensitization of drug-resistant tumor cells by subtoxic doses of sensitizing chemotherapeutic drugs may result in tumor regression by the host immune system...
  31. ncbi BALB/C mice injected with LSTRA leukemic cell line are cured by in vivo treatment with IL-2 + GM-CSF
    R Rojas
    Department of Hematology, Reina Sofi a University Hospital, Avda Menendez Pidal s n, 14004 Cordoba, Spain
    Leuk Res 27:351-7. 2003
    ..We show that BALB/C mice injected with LSTRA cell line can be cured by in vivo activation with IL-2 + GM-CSF depending on the cell dose injected. The curability of leukemia was confirmed at the molecular level with a PCR method...
  32. ncbi A role for the src family kinase Fyn in NK cell activation and the formation of the repertoire of Ly49 receptors
    Bente Lowin-Kropf
    Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Epalinges, Switzerland
    Eur J Immunol 32:773-82. 2002
    ..NK cells may acquire Ly49 receptors until they generate sufficient inhibitory signals to balance their activation levels. Such a process would ensure the induction of NK cell self-tolerance...
  33. ncbi The nonclassical major histocompatibility complex molecule Qa-2 protects tumor cells from NK cell- and lymphokine-activated killer cell-mediated cytolysis
    Eugene Y Chiang
    Center for Immunology, Departments of Microbiology and Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA
    J Immunol 168:2200-11. 2002
    ..We propose that Q9 expressed on melanoma cells serves as a ligand for yet unidentified NK inhibitory receptor(s) expressed on NK1.1(+) NK/T cells...
  34. ncbi CD1d-independent NKT cells in beta 2-microglobulin-deficient mice have hybrid phenotype and function of NK and T cells
    Motoi Maeda
    Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    J Immunol 172:6115-22. 2004
    ..Thus, CD1d-independent NKT cells are significantly different from CD1d-restricted NKT cells. They have hybrid phenotypes and functions of NK cells and T cells...
  35. ncbi Characterization of murine cathepsin W and its role in cell-mediated cytotoxicity
    Jennifer K Ondr
    Department of Internal Medicine, Washington University School of Medicine, St Louis, Missouri 63110, USA
    J Biol Chem 279:27525-33. 2004
    ..In addition, mCtsW deficiency does not alter the susceptibility of cytotoxic lymphocytes to suicide or fratricide after degranulation. Thus, mCtsW does not have a unique role in target cell apoptosis or cytotoxic cell survival in vitro...
  36. ncbi Murine B-cell leukemia lymphoma (BCL1) cells as a target for NK cell-mediated immunotherapy
    L Weiss
    Department of Bone Marrow Transplantation and Cancer Immunotherapy, Cell Therapy and Transplantation Immunobiology Research Center, Hadassah University Hospital, Jerusalem, Israel
    Bone Marrow Transplant 33:1137-41. 2004
    ..BCL1 cells express ligands for NKp46 on the cell surface membrane and they are sensitive to allogeneic but not syngeneic IL-2 activated natural killer cells...
  37. ncbi Immunological and clinical effects of post-transplant G-CSF versus placebo in T-cell replete allogeneic blood transplant patients: results from a randomized double-blind study
    S S Joshi
    Department of Genetics, University of Nebraska Medical Center, Omaha, NE 986395, USA
    Cytotherapy 5:542-52. 2003
    ..This report describes the outcome and immune functions of a total of 50 HLA-matched related donor allogeneic blood stem-cell transplantation patients who received post-transplant G-CSF (10 microg/kg) or placebo...
  38. ncbi Decreased immune functions of blood cells following mobilization with granulocyte colony-stimulating factor: association with donor characteristics
    S S Joshi
    Department of Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, USA
    Blood 98:1963-70. 2001
    ..These results suggest a decreased immune function in G-CSF-mobilized BSC harvests and warrant further studies to correlate these data with clinical outcome...
  39. ncbi [Phenotypical analysis of effector cells on nonspecific cancer cell therapy]
    Toshimi Sudo
    Dept of Gastroenterological Surgery, Tokyo Women s Medical University
    Gan To Kagaku Ryoho 30:1817-20. 2003
    ....
  40. ncbi Characterization of human tumor-infiltrating lymphocytes expanded in hollow-fiber bioreactors for immunotherapy of cancer
    C C Malone
    Patty and George Hoag Cancer Center, One Hoag Drive, Building 41, Newport Beach, CA 92658, USA
    Cancer Biother Radiopharm 16:381-90. 2001
    ..This work confirms that hollow-fiber bioreactors are a suitable alternative to semi-permeable bags and roller bottle systems for the expansion of human TIL for therapeutic use in cancer patients...
  41. ncbi Renal cell carcinoma-infiltrating natural killer cells express differential repertoires of activating and inhibitory receptors and are inhibited by specific HLA class I allotypes
    Julia S Schleypen
    Institute of Molecular Immunology, GSF National Research Center for the Environment and Health, Munich, Germany
    Int J Cancer 106:905-12. 2003
    ..Therefore, NK cells infiltrating tumor tissues have an inherent ability to recognize transformed cells, but they require cytokine activation and are sensitive to inhibition by IR ligands...
  42. ncbi Selective reduction of natural killer cells and T cells expressing inhibitory receptors for MHC class I in the livers of patients with hepatic malignancy
    Suzanne Norris
    Education and Research Centre, St Vincent s University Hospital, Elm Park, Dublin, Ireland
    Cancer Immunol Immunother 52:53-8. 2003
    ..Our results suggest that, while hepatic CD56(+) T cells are not expanded in malignancy, downregulation of KIR and CD94 expression may be a mechanism by which the hepatic immune system can be activated to facilitate tumour rejection...
  43. ncbi Anti-apoptotic seminal vesicle protein IV inhibits cell-mediated immunity
    M P Fuggetta
    Institute of Neurobiology and Molecular Medicine INMM, CNR, Area Ricerca Roma Tor Vergata, Via del Fosso del Cavaliere 100, Rome, Italy
    J Reprod Immunol 78:85-93. 2008
    ..These findings indicate that the protein SV-IV has a marked in vitro inhibitory effect on NK, LAK and CTL cytotoxicity, providing a better understanding of its immune regulatory functions...
  44. pmc A novel multiparametric flow cytometry-based cytotoxicity assay simultaneously immunophenotypes effector cells: comparisons to a 4 h 51Cr-release assay
    G G Kim
    University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    J Immunol Methods 325:51-66. 2007
    ..The FCC assay has a potential for providing information about molecular interactions underlying target cell lysis and thus becoming a major tool for studies of disease pathogenesis as well as development of novel immune therapies...
  45. ncbi Strain- and age-dependent natural and activated in vitro cytotoxicity in athymic nude mice
    C Radzikowski
    Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw
    APMIS 102:481-8. 1994
    ..FACS analyses of antigenic markers revealed an increased number of T cells in spleens of aged immunodeficient mice, with differences between mice of the examined strains and a decrease in the number of NK cells in aged mice...
  46. ncbi Metastasis of mouse T lymphoma cells is controlled by the level of major histocompatibility complex class I H-2Dk antigens
    T Vandendriessche
    Laboratory of Cellular Immunology, Free University of Brussels, Sint Genesius Rhode, Belgium
    Int J Cancer 58:217-25. 1994
    ..We conclude that a NK-dependent mechanism accounts for the association between differential H-2Dk antigen expression and metastasis...
  47. ncbi Ganoderma lucidum polysaccharides enhance the function of immunological effector cells in immunosuppressed mice
    Xiao Ling Zhu
    Department of Pharmacology, School of Basic Medical Science, Peking University Health Science Center, 38 Xueyuan Road, Beijing 100083, PR China xiaolingzhu88yahoo com cn
    J Ethnopharmacol 111:219-26. 2007
    ....
  48. ncbi Combined effect of cisplatin and lymphokine-activated killer cells on A549 cells of non-small cell lung cancer
    O S Zhukova
    N N Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
    Bull Exp Biol Med 144:231-4. 2007
    ..Cisplatin in noncytotoxic concentrations did not increase lytic activity of lymphokine-activated killer cells...
  49. ncbi Enhancement of lymphocyte proliferation and IL-2 receptor expression by a processed form (GM-1/P) of monosialoganglioside GM-1
    A Giuffrida
    Department of Experimental Medicine, University of Rome, La Sapienza, Italy
    Immunopharmacol Immunotoxicol 12:565-82. 1990
    ..61) directed against the p55 subunit of murine IL-2r. 29% PC.61+ cells were found in IL-2 cultures from treated spleen cells...
  50. ncbi Cytotoxic cells in immunodeficient athymic mice
    W Budzynski
    Department of Tumor Immunology, Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw
    Immunopharmacol Immunotoxicol 16:319-46. 1994
    ....
  51. ncbi Anti-tumoral capabilities of effector cells after IFN-alpha or CpG-motif treatment of cocultured dendritic cells
    Michael Erhardt
    Department of Internal Medicine I, University of Bonn, Bonn, Germany
    Arch Immunol Ther Exp (Warsz) 54:403-9. 2006
    ..One recently published approach to optimize the immunological functions of the DC/CIK cell system is the replacement of interleukin (IL)-4 by interferon (IFN)-alpha in the maturation process of the DCs...
  52. ncbi Effect of ASTA-Z 7575 (INN Maphosphamide) on human lymphokine-activated killer cell induction
    K P Singh
    Preventive Toxicology Division, Industrial Toxicology Research Centre, Lucknow, India
    Immunopharmacol Immunotoxicol 15:525-38. 1993
    ..The significant therapeutic benefit in the cancer patient may be achieved by the low dose regimen of Cy and IL-2 because it has no deleterious effect on the induction and function of LAK cells...
  53. ncbi Purification and cloning of a novel serine protease, RNK-Met-1, from the granules of a rat natural killer cell leukemia
    M J Smyth
    Cellular Cytotoxicity Laboratory, Austin Research Institute, Austin Hospital, Heidelberg, Victoria, Australia
    J Biol Chem 267:24418-25. 1992
    ..These data indicate that RNK-Met-1 is a serine protease with unique activity that is expressed in the granules of large granular lymphocytes...
  54. pmc Monoclonal antibody to a triggering structure expressed on rat natural killer cells and adherent lymphokine-activated killer cells
    W H Chambers
    Pittsburgh Cancer Institute, University of Pittsburgh, Pennsylvania 15213
    J Exp Med 169:1373-89. 1989
    ....
  55. ncbi [Interstitial lung disease and lung cancer]
    Nobuhisa Ishikawa
    Department of Molecular and Internal Medicine, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan
    Gan To Kagaku Ryoho 37:6-9. 2010
    ..The pathogenesis of lung cancer in ILDs is unclear, but some genetic factors seem to be involved. Further studies are needed to clarify the causes and the mechanisms that link ILDs and lung cancer...
  56. ncbi Interleukin-2 and the IL-2 receptor: new insights into structure and function
    W A Kuziel
    Howard Hughes Medical Institute, Department of Medicine, Durham, North Carolina
    J Invest Dermatol 94:27S-32S. 1990
    ..However, the actual mechanism of signal transduction in the IL-2/IL-2R system remains undefined. IL-2R beta is a member of a novel family of cytokine-receptor proteins that includes receptors for IL-4, IL-6, and erythropoietin...
  57. ncbi Induction of peptide-specific immune response in patients with primary malignant melanoma of the esophagus after immunotherapy using dendritic cells pulsed with MAGE peptides
    Yuji Ueda
    Department of Surgery and Oncology of Digestive System, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
    Jpn J Clin Oncol 37:140-5. 2007
    ..This case report warrants further clinical evaluation of this immunotherapy for PMME...
  58. ncbi Uterine natural killer cells in species with epitheliochorial placentation
    H Engelhardt
    Department of Animal and Poultry Science, University of Guelph, Ont, Canada
    Nat Immun 15:53-69. 1996
    ..However, a common theme among these species is that the presence of the genetically foreign conceptus seems to activate uterine lymphocytes and to redirect their activities towards the promotion of fetal survival...
  59. ncbi Experimental study on the treatment of intracerebral glioma xenograft with human cytokine-induced killer cells
    Peng Wang
    Department of Neurosurgery and Neuro Oncology, Key Laboratory of Cancer Prevention and Therapy, Cancer Institute and Hospital of Tianjin Medical University, Tianjin 300060, China
    Cell Immunol 253:59-65. 2008
    ..Local injection of CIKs does not produce severe damage to normal brain tissue and is likely to be used in clinical adoptive immunotherapy of intracerebral glioma...
  60. ncbi Specific targeting immunotherapy of cancer with bispecific antibodies
    T Kudo
    Cell Resource Center for Biomedical Research, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
    Tohoku J Exp Med 188:275-88. 1999
    ..of two kinds of BsAbs (anti-tumor x anti-CD3 plus anti-tumor x anti-CD28) together with lymphokine activated killer cells with a T cell phenotype (T-LAK cells) inhibited growth of human xenotransplanted tumors in severe ..
  61. ncbi Receptor modulation and early signal transduction events in cytotoxic T lymphocytes inactivated by sensitive target cells
    G A Hommel-Berrey
    Department of Medicine, Indiana University School of Medicine, Indianapolis 46202
    J Immunol 147:3237-43. 1991
    ..Our data suggest that TC-induced inactivation of CTL may be due to the modulation of key membrane molecules and the lack of certain secondary messengers involved in signal transduction...
  62. ncbi Augmentation by tumor necrosis factor alpha of the systemic therapeutic effect of lymphokine-activated killer cells in adoptive immunotherapy of murine tumor
    K Kato
    Department of Hygienic Chemistry, Pharmaceutical Institute, Tohoku University, Sendai
    Jpn J Cancer Res 82:464-9. 1991
    ..e., growth inhibition of tumor nodules and prolongation of survival. These results indicated that appropriately timed pretreatment of tumor-bearing mice with TNF alpha augmented the anti-tumor efficacy of LAK cells...
  63. ncbi T cell receptor-independent cell-mediated cytotoxicity by nude mouse lymphokine-activated killer cells
    T Nishimura
    Department of Immunology, Tokai University School of Medicine, Isehara
    Jpn J Cancer Res 82:448-55. 1991
    ..Monoclonal antibody against lymphocyte function-associated antigen (LFA-1) molecule can block the cytotoxicity of Nude-LAK cells, indicating an important role of such accessory molecules in Nude-LAK cell-mediated cytotoxicity...
  64. ncbi In vitro and in vivo antitumor effects of recombinant bispecific antibodies based on humanized anti-EGFR antibody
    Yasuhiro Watanabe
    Division of Gastroenterological Surgery, Department of Surgery, Graduate School of Medicine, Tohoku University, Sendai 980 8574, Japan
    Oncol Rep 26:949-55. 2011
    ..With an in vivo effect comparable to hEx3-scFv-Fc and its realistic molecular weight, hEx3-scDb-Fc shows promise as a novel recombinant therapeutic antibody and may be modified to enhance its potency by prevention of steric hindrance...
  65. ncbi Use of interleukin-2 in advanced renal carcinoma: meta-analysis and review of the literature
    M Malaguarnera
    Institute of Internal Medicine and Geriatrics, University of Catania, Italy
    Eur J Clin Pharmacol 57:267-73. 2001
    ....
  66. ncbi Granzyme B and the downstream granzymes C and/or F are important for cytotoxic lymphocyte functions
    Paula A Revell
    Division of Oncology, Department of Internal Medicine, Siteman Cancer Center, Washington University School of Medicine, St Louis Children s Hospital, St Louis, MO 63110, USA
    J Immunol 174:2124-31. 2005
    ..These results suggest that the retained PGK-neo cassette in the GzmB gene causes a knockdown of GzmC and F expression, and also suggest that these granzymes are relevant for the function of cytotoxic lymphocytes in vitro and in vivo...
  67. ncbi Structure, expression and function of HLA-G in renal cell carcinoma
    Barbara Seliger
    Martin Luther University Halle Wittenberg, Institute of Medical Immunology, Magdeburger Strasse 2, 06112 Halle, Germany
    Semin Cancer Biol 17:444-50. 2007
    ..Functional studies using natural killer cells, lymphokine activated killer cells as well as antigen-specific CD8+ cytotoxic T lymphocytes demonstrated that HLA-G expression prevents ..
  68. ncbi CD4+ T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection
    P A Cohen
    Center for Surgery Research, Cleveland Clinic Foundation, OH 44195, USA
    Crit Rev Immunol 20:17-56. 2000
    ....
  69. ncbi [A case of recurrent malignant melanoma of esophagus responsive to combined chemotherapy, radiotherapy and cellular immunotherapy]
    Satoru Motoyama
    Dept of Esophageal Surgery, Akita University Hospital, Japan
    Gan To Kagaku Ryoho 38:639-42. 2011
    ..In this patient, the recurrent tumors responded well to trimodal therapy consisting of chemotherapy, radiotherapy and cellular immunotherapy...
  70. ncbi Cloning and characterization of the 2B4 gene encoding a molecule associated with non-MHC-restricted killing mediated by activated natural killer cells and T cells
    P A Mathew
    Laboratory of Molecular Pathology, University of Texas Southwestern Medical Center at Dallas 75235
    J Immunol 151:5328-37. 1993
    ..The 2B4 gene has been mapped to mouse chromosome 1 by analysis of 2B4 expression in recombinant inbred mouse strains...
  71. ncbi [Replacement of the constant region gene of a novel anti-CEA antibody and characterization of its biological activity]
    Jian Huang
    Department of Biochemistry, Guilin Medical College, Guilin 541004, China
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 22:650-3. 2006
    ..To convert the subclass of a novel anti-CEA antibody, C2-45, from IgG4 to IgG1, and to increase its biological activity...
  72. ncbi Molecular cloning of rat cytolysin
    H Ishikawa
    Department of Immunology, Juntendo University, School of Medicine, Tokyo, Japan
    J Immunol 143:3069-73. 1989
    ..9% nucleotide and 84.9% amino acid identity). Northern blot hybridization analysis indicates that cytolysin mRNA is expressed in rat lymphocytes (lymphokine-activated killer cells and LGL cells) and LGL cell lines...
  73. ncbi Expansion of cytotoxic CD3+ CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation
    J C Alvarnas
    Department of Medicine, Stanford University Medical Center, California, USA
    Biol Blood Marrow Transplant 7:216-22. 2001
    ..CIK cells may be expanded from granulocyte colony-stimulating factor-mobilized PBPCs of patients undergoing autologous HCT. CIK cells may provide a potent tool for use in posttransplantation adoptive immunotherapy...
  74. ncbi IL-2R beta agonist P1-30 acts in synergy with IL-2, IL-4, IL-9, and IL-15: biological and molecular effects
    R Eckenberg
    Unité d Immunogénétique Cellulaire, Institut Pasteur, Paris, France
    J Immunol 165:4312-8. 2000
    ..Our data suggest that p1-30R (IL-2Rbeta)(2) and intermediate affinity IL-2R (IL-2Rbetagamma), when simultaneously expressed at the cell surface, may induce complementary signal transduction pathways and act in synergy...
  75. pmc Efficacy of chemoimmunotherapy with cyclophosphamide, interleukin-2 and lymphokine activated killer cells in an intraperitoneal murine tumour model
    A M Eggermont
    Division of Cancer Treatment, National Cancer Institute, Bethesda, Maryland 20892
    Br J Cancer 58:410-4. 1988
    ..Further research should be directed at the design of treatment schedules based on repetitive courses of chemoimmunotherapy associated with little toxicity...
  76. ncbi GM-CSF and IL-2 combination as adjuvant therapy in cutaneous melanoma: early results of a phase II clinical trial
    E George Elias
    The Maryland Melanoma Center, Franklin Square Hospital Center, Baltimore, Maryland, USA
    Oncology (Williston Park) 19:15-8. 2005
    ..The combination treatment regimen of GM-CSF and IL-2 with or without autologous vaccine used adjuvantly appears to benefit high-risk melanoma patients; further clinical testing of this regimen is warranted...
  77. ncbi Cloning and expression of murine IL-12
    D S Schoenhaut
    Department of Molecular Genetics, Roche Research Center, Hoffmann La Roche Inc, Nutley, NJ 07110 1197
    J Immunol 148:3433-40. 1992
    ..These results indicate that the observed inability of human IL-12 to act on murine cells is largely determined by the p35 subunit...
  78. ncbi Phase I trial of oral talactoferrin alfa in refractory solid tumors
    Teresa G Hayes
    Michael E DeBakey VA Medical Center, Baylor College of Medicine, Houston, Texas, USA
    Invest New Drugs 24:233-40. 2006
    ..The purpose of the present study was to evaluate the safety and tolerability of talactoferrin alfa (talactoferrin; TLF) in humans, as well as pharmacokinetics and pharmacodynamics...
  79. pmc Opposite roles of metastasin (S100A4) in two potentially tumoricidal mechanisms involving human lymphocyte protein Tag7 and Hsp70
    Elena A Dukhanina
    Laboratory of Molecular Immunogenetics of Cancer, Institute of Gene Biology, Russian Academy of Sciences, University of Oslo, 34 5 Vavilova Street, Moscow 119334, Russia
    Proc Natl Acad Sci U S A 106:13963-7. 2009
    ..Thus, our models suggest that interactions between the three proteins in different situations may have opposite functional outcomes as regards antitumor defense, immune escape, and metastasis...
  80. ncbi Role for heat shock proteins in the immune response to measles virus infection
    Michael J Oglesbee
    Department of Veterinary Biosciences, The Ohio State University, Columbus, Ohio 43210, USA
    Viral Immunol 15:399-416. 2002
    ..the infected cell, HSPs are uniquely expressed on the cell surface, where they represent targets of lymphokine activated killer cells. Necrosis of the infected cell releases complexes of HSP and viral protein, which, in turn, binds ..
  81. ncbi Antimicrobial peptides as potential new antifungals
    F M Muller
    Institut für Molekulare Infektionsbiologie, Universitat Wurzburg, Germany
    Mycoses 42:77-82. 1999
    ..interact with a variety of host cells and can increase the activity of natural killer and lymphokine activated killer cells. Pretreatment of polymorphonuclear neutrophil leukocytes (PMN) or monocytes with these AP also may ..
  82. ncbi Novel approaches using natural killer cells in cancer therapy
    Garnet Suck
    Division of Biomedical Sciences, Johns Hopkins in Singapore, 31 Biopolis Way, 02 01 The Nanos, Singapore, Singapore
    Semin Cancer Biol 16:412-8. 2006
    ..Novel clinical approaches aim to overcome limitations of original therapies, which have utilized lymphokine activated killer cells or systemic cytokine treatments...
  83. ncbi Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells
    J W Heusel
    Department of Medicine, Jewish Hospital, St Louis, Missouri 63110
    Cell 76:977-87. 1994
    ..We conclude that gzm B serves a critical and nonredundant role for the rapid induction of target cell DNA fragmentation and apoptosis by alloreactive cytotoxic T lymphocytes...
  84. pmc Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor
    U Gubler
    Department of Molecular Genetics, Roche Research Center, Hoffmann La Roche, Inc, Nutley, NJ 07110
    Proc Natl Acad Sci U S A 88:4143-7. 1991
    ..Since this heterodimeric protein displays the properties of an interleukin, we propose that CLMF be given the designation interleukin 12...
  85. ncbi NKG2D-dependent effector function of bronchial epithelium-activated alloreactive T-cells
    K Kraetzel
    Dept of Internal Medicine II, University of Regensburg, Franz Josef Strauss Allee 11, Regensburg, 93053 Germany
    Eur Respir J 32:563-70. 2008
    ..The present data imply that the respiratory epithelium has an antigen presenting function and directly alloactivates cytotoxic CD8+ T-cells that show nonclassical effector function...
  86. ncbi Advanced donor-origin melanoma in a renal transplant recipient: immunotherapy, cure, and retransplantation
    M G Suranyi
    Department of Immunology, Princess Alexandra Hospital, Brisbane, Australia
    Transplantation 66:655-61. 1998
    ..When florid allograft rejection was in progress, the allograft was removed, before it was recognized that the transplanted melanoma was not being simultaneously rejected...
  87. ncbi In vitro effects of GSM modulated radiofrequency fields on human immune cells
    Helga Tuschl
    ARC Seibersdorf Research GmbH, Seibersdorf, Austria
    Bioelectromagnetics 27:188-96. 2006
    ..3) The cytotoxicity of lymphokine activated killer cells (LAK cells) against a tumor cell line was determined in a flow cytometric test...
  88. ncbi Establishment of hepatocarcinoma cell line transfected by the B7 gene and its biocharacteristics
    You Zhu Li
    First Clinical Hospital, Jilin University, Changchun 130021, China
    Hepatobiliary Pancreat Dis Int 2:278-80. 2003
    ..To study the function of costimulation sign in tumor immunology and construct the new cell line B7+ Smmc7721...
  89. ncbi Highly effective recombinant format of a humanized IgG-like bispecific antibody for cancer immunotherapy with retargeting of lymphocytes to tumor cells
    Ryutaro Asano
    Department of Biomolecular Engineering, Graduate School of Engineering, Tohoku University, Sendai 980 8579, Japan
    J Biol Chem 282:27659-65. 2007
    ..The high potency of hEx3-scFv-Fc may translate into improved antitumor therapy and lower costs of production because of the smaller doses needed...
  90. ncbi Differential expression of cell adhesion molecules CD54/CD11a and CD58/CD2 by human melanoma cells and functional role in their interaction with cytotoxic cells
    M Altomonte
    Advanced Immunotherapeutics Unit, C R O, Aviano, Italy
    Cancer Res 53:3343-8. 1993
    ....
  91. ncbi Role of fibrinogen covalently associated with cell membrane in blood-borne lung tumor colony formation of murine mammary carcinoma cells
    S Y Lee
    Department of Natural Sciences, Chemistry Section, College of Medicine, Catholic University of Korea, Seoul, Korea
    Oncology 59:238-44. 2000
    ..These results provide information on the impact of fibrin stability on blood-borne lung tumor colony formation of SCK mammary carcinoma cells...
  92. ncbi Potential role of natural killer cell receptor-expressing cells in immunotherapy for leukemia
    Junji Tanaka
    Hematology and Oncology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
    Int J Hematol 81:6-12. 2005
    ..We review recent developments in the biology and clinical application of NKR-expressing cells, such as NK cells, lymphokine-activated killer cells, cytokine-induced killer cells, NKT cells, and other NKR-expressing cells...
  93. ncbi A new procedure for large scale production and freezing of lymphokine activated killer (LAK) cells to be used in adoptive immunotherapy of cancer
    C Gambacorti-Passerini
    Division of Experimental Oncology D, Istituto Nazionale Tumori, Milan, Italia
    Tumori 74:523-30. 1988
    ..With this procedure therefore large quantities of lymphokine activated killer cells (LAK) can be easily produced to be used in adoptive immunotherapy trials.
  94. ncbi A role for growth hormone and prolactin in leukaemia and lymphoma?
    R Hooghe
    Department of Pharmacology, Medical School, Free University of Brussels VUB, Belgium
    Cell Mol Life Sci 54:1095-101. 1998
    ....
  95. ncbi Cooperation between CD44 and LFA-1/CD11a adhesion receptors in lymphokine-activated killer cell cytotoxicity
    G Matsumoto
    Amgen Institute, and Department of Medical Biophysics and Immunology, University of Toronto, Ontario, Canada
    J Immunol 160:5781-9. 1998
    ..These data also indicate that distinct adhesion receptors cooperate to mediate binding between effector and target cells required for the initiation of "natural" cytotoxicity...
  96. ncbi Immunotherapy of human neuroblastoma using umbilical cord blood-derived effector cells
    Avadhut D Joshi
    Department of Genetics, Cell Biology and Anatomy, College of Medicine, University of Nebraska Medical Center, Omaha, NE 68198 6395, USA
    J Neuroimmune Pharmacol 2:202-12. 2007
    ..01) inhibition of tumor growth and increased overall survival. Thus, these results demonstrate the potential of UCB-derived effector cells against human neuroblastoma and warrant further preclinical studies...
  97. ncbi [Isolation and purification of antibacterial polypeptides from human LAK cells]
    Qi Zhang
    Research Unit of Infection and Immunity, West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu 610041, China
    Hua Xi Yi Ke Da Xue Xue Bao 33:87-90. 2002
    ..To isolate and purify new antibiotic peptides from human lymphokine activated killer (LAK) cells...
  98. ncbi Expression and one-step purification of bovine interleukin-21 (IL-21) in silkworms using a hybrid baculovirus expression system
    Yoshihiro Muneta
    Department of Immunology, National Institute of Animal Health, 3 1 5 Kannondai, Tsukuba, Ibaraki 305 0856, Japan
    Biotechnol Lett 26:1453-8. 2004
    ..The bovine IL-21 produced by silkworms strongly induced NK cell proliferation using a human NK cell-line, NK0, and enhanced the lymphokine activated killer (LAK) activity of bovine peripheral blood mononuclear cells...
  99. ncbi The in vitro generation of Ph1+ ALL-specific HLA-A24-restricted cytotoxic T lymphocytes using a synthetic 16 mer minor bcr-abl peptide
    Masao Hagihara
    Department of Hematology and Rheumatology, Tokai University School of Medicine, Bohseidai, Isehara, Kanagawa 259 1193, Japan
    Leuk Res 27:253-7. 2003
    ..Those CTLs consisted predominantly of CD8+ T cells whose cytotoxicity could be neutralized by monoclonal antibodies to HLA-class I or HLA-A24, and also produced interferon (IFN)-gamma after being stimulated with peptide-pulsed DCs...
  100. ncbi Xenogeneic beta 2-microglobulin substitution alters NK cell function
    Loralyn A Benoit
    Department of Immunology, University of Toronto, Toronto, Ontario, Canada
    J Immunol 179:1466-74. 2007
    ....
  101. ncbi DNA repair enzymes and cytotoxic effects of temozolomide: comparative studies between tumor cells and normal cells of the immune system
    E Pagani
    Istituto Dermopatico dell Immacolata IDI IRCCS, Rome, Italy
    J Chemother 15:173-83. 2003
    ..However, the use of OGAT inhibitors to potentiate the antitumor activity of TMZ might result in a concomitant increase of the immunosuppressive effects of the drug, thus reducing the relative TIFTI...

Research Grants16

  1. Regulation of urokinase receptor expression in colon cancer
    Douglas D Boyd; Fiscal Year: 2010
    ..In Specific Aim # 2, we will determine whether altered glycosylation of u-PAR in the u-PARdeficient population is an initial stimulus for lysosomal degradation of the immature protein. ..
  2. DEVELOPING T CELLS CLONES CYTOTOXIC TO SARCOMAS
    Michael Mastrangelo; Fiscal Year: 1990
    ..It is hoped that these studies will lead to a better understanding of the biology of sarcomas and provide reagents for clinical trials...
  3. IL7 AND IL7R TARGETED THERAPEUTIC AGENTS FOR LEUKEMIA
    John Murphy; Fiscal Year: 2000
    ..and induce signal transduction events in both pre-B and T cell progenitors, cytotoxic T cells, lymphokine activated killer cells, myeloid cells, and a variety of leukemia and lymphoma cells freshly isolated from patients...
  4. Lymphodepletion for Melanoma Patients
    Marc Ernstoff; Fiscal Year: 2007
    ..Adoptive cellular therapies with lymphokine activated killer cells (LAK) or tumor infiltrating lymphocytes (TIL) and IL-2 have been employed to overcome inadequate ..
  5. M40403 and IL-2 Induced Hypotension
    Daniela Salvemini; Fiscal Year: 2001
    ..In contrast, M40403 increased IL-2 mediated activation of the lymphokine activated killer cells as demonstrated by in vitro & in vivo experiments & synergized with the anti-tumor effects ..
  6. HUMAN LYMPHOKINE-ACTIVATED KILLER CELLS
    JANET RANSOM; Fiscal Year: 1991
    ..Each patient that is leukopheresed will yield approximately 3-7 X 1010 cells daily. The number of patients and any modifications of cell activation will be at the discretion of the Project Officer...
  7. THE CELLULAR STRESS RESPONSE IN VIRAL ENCEPHALITIS
    Michael Oglesbee; Fiscal Year: 2008
    ..The experimental system uses measles virus, but the work has potential broad relevance to other viruses that infect brain. [unreadable] [unreadable] [unreadable] [unreadable]..
  8. T CELL ACTIVATION FOR CANCER IMMUNOTHERAPY
    Alfred Chang; Fiscal Year: 2008
    ..We have extensive experience in the conduct of adoptive immunotherapy and vaccine trials in humans that will allow translation of these findings. ..
  9. Role of DPPI & Serine Proteases in Inflammatory Diseases
    Christine Pham; Fiscal Year: 2007
    ..We also hypothesize that decreased expression of complement regulators in the kidney mav be a determinant that influences the severity of tissue damage in the target organ. ..
  10. T CELL THERAPY OF HUMAN RENAL CELL CANCER
    Alfred Chang; Fiscal Year: 2007
    ..Lloyd Stoolman. Dr. Stoolman plans to examine novel methods to enrich tumor reactive lymphoid cells based upon adhesion marker expansion utilizing samples generated from this proposal. ..
  11. MBSR for Stress-Related Immune Dysregulation in Cancer
    LINDA JANUSEK; Fiscal Year: 2004
    ..Such an approach has the potential to lead to not only better cancer control but also to a better quality of life for cancer. ..
  12. RECONSTITUTION OF CMV IMMUNITY IN HIV-INFECTED HOSTS
    Stanley Riddell; Fiscal Year: 2001
    ....
  13. RESEARCH TRAINING IN TRANSLATIONAL TUMOR IMMUNOLOGY
    Alfred Chang; Fiscal Year: 2005
    ..Predoctoral and postdoctoral trainees should leave the program well prepared for academic careers focused on translational aspects of immunologic research as it pertains to the development of new strategies for the treatment of cancer. ..
  14. GLOBIN GENE TRANSFER FOR THERAPY OF SICKLE CELL ANEMIA
    Michel Sadelain; Fiscal Year: 2004
    ....